Propionyl-L-Carnitine

Propionyl-L-carnitine (PLC) is the propionyl acyl ester of levocarnitine, the biologically active form of carnitine ^[2][3]. Carnitine itself is a quaternary ammonium compound, built by the body from the amino acid lysine, that most mammals rely on to carry long-chain fatty acids across the mitochondrial membrane so they can be burned for energy. Chemically PLC belongs to the family of acylcarnitines, in which a short-chain fatty acid, here propionate, is attached to the carnitine backbone. This structure lets it act both as a source of carnitine and as a supplier of propionyl groups that can feed into the citric acid cycle.

Interest in PLC grew from the finding that people with peripheral arterial disease (PAD) accumulate acylcarnitine intermediates in the skeletal muscle of the affected limbs, a marker of disturbed oxidative metabolism; those with the greatest build-up tend to have the most impaired walking performance ^[3]. This reframed claudication as partly a metabolic problem rather than a simple consequence of reduced blood flow, and it prompted trials of carnitine compounds. In direct comparisons, PLC proved more effective than plain L-carnitine at extending treadmill walking distance, and two large multicentre trials together enrolling several hundred patients reported greater improvements in initial and maximal walking distance with PLC than with placebo, along with gains in quality of life ^[3].

A 2021 Cochrane systematic review pooled twelve randomized controlled trials with more than fourteen hundred participants, comparing PLC, given by mouth or by infusion, against placebo or L-carnitine ^[1]. It found that PLC produced mild to moderate improvements in both pain-free and maximal walking distance and a small rise in the ankle brachial index, with a safety profile similar to placebo and only moderate overall certainty because of clinical heterogeneity and heavy industry sponsorship of the underlying studies ^[1]. The reviewers concluded that PLC might be considered as an alternative or add-on when standard therapies are unsuitable, while noting the absence of trials comparing it directly against exercise, surgery, or established drugs ^[1].

PLC is marketed in parts of Europe as a prescription cardiovascular medicine, and guideline updates such as the Trans-Atlantic Inter-Society Consensus have positioned it as an adjunct to physical training for claudication ^[2]. It has not received approval from regulators in the United States ^[3]. Across the trial literature it has been administered both orally and, in some settings, by intravenous infusion, while carnitine compounds more broadly are also sold as dietary supplement ingredients ^[1][3].

Generally well tolerated; side effects are mild and include nausea, GI upset, and occasionally a fishy body odor at high doses. Like other carnitines, gut bacteria can convert some of it to TMAO, a compound debated for cardiovascular risk, though carnitine's vascular benefits complicate that picture. People with kidney disease or on thyroid or blood-thinning medication should use it with care.